Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching

Immune checkpoint inhibitors are being increasingly used in the management of advanced non-small cell lung cancer (NSCLC). Identifying patients most likely to respond to these agents has become an increasingly important area of investigation.